A new study compared all-cause health care costs and health resource utilization associated with first targeted therapies for advanced renal cell carcinoma.
Transforming Possible Outcomes into Real Results
Shaji K Kumar, MD, explains the various considerations for management of multiple myeloma in different disease settings.
Subjective assessment of solid tumor response to therapy may misinform the intended benefit and limit the potential role of real-world evidence in value-based care research.
Long-term safety and efficacy data show that a CAR T-cell therapy produces high response rates in highly pretreated adult patients with relapsed or refractory DLBCL.
In a new study, researchers identified factors associated with high economic burden for patients with treated diffuse large B-cell lymphoma and follicular lymphoma.
A new diabetes blood test that analyzes glucose and HbA1c levels may alter the current diagnostic guidelines.
A recent study sought to determine whether increased spending correlates with improved survival for patients with different cancer types in Oncology Care Model-defined episodes.
Palliative care interventions and inpatient support may be inadequate among hospitalized patients with solid and hematologic cancers.
Using the current World Health Organization threshold criteria, a new study examined whether osimertinib is cost-effective as a first-line therapy of EGFR-mutated advanced non-small cell lung cancer.